Article Text

PDF
Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study
  1. M R Kraus1,
  2. A Schäfer1,
  3. K Schöttker1,
  4. C Keicher1,
  5. B Weissbrich2,
  6. I Hofbauer3,
  7. M Scheurlen1
  1. 1
    Medizinische Klinik und Poliklinik II, Department of Gastroenterology and Hepatology, University of Würzburg, Würzburg, Germany
  2. 2
    Institute for Virology and Immunobiology, University of Würzburg, Würzburg, Germany
  3. 3
    Central Pharmacy, University of Würzburg, Würzburg, Germany
  1. Dr M R Kraus, PhD, Medizinische Klinik und Poliklinik II, Würzburg University, Klinikstr 6–8, 97070 Würzburg, Germany; kraus_m{at}klinik.uni-wuerzburg.de

Abstract

Background: Interferon-induced depression represents a major complication in antiviral treatment of chronic hepatitis C virus (HCV) infection.

Aim: To evaluate in a placebo-controlled study the efficacy of a selective serotonin reuptake inhibitor (SSRI) in HCV patients on antiviral therapy with interferon-associated depression.

Methods: 100 HCV outpatients were included in a randomised, double-blind, placebo-controlled study. During interferon therapy (peginterferon alfa-2b plus ribavirin), depression was monitored using the Hospital Anxiety and Depression Scale (HADS). Patients with clinically relevant interferon-induced depression (HADS ⩾9) were randomly assigned to placebo or citalopram (SSRI, 20 mg/day).

Results: In 28 patients (28%), HADS scores increased to >8 during interferon therapy. They were treated with placebo (n  =  14) or SSRI (n  =  14). HADS scores declined significantly in SSRI patients within four weeks of therapy (p<0.001) but not in placebo patients. This difference between subgroups was statistically significant (p = 0.032). Unblinding became necessary in five placebo patients as a result of intolerable depression. Rescue medication (20 mg citalopram) led to a significant decrease in HADS scores (p = 0.008). All citalopram patients were able to complete interferon therapy as planned. As an interim analysis showed a significant superiority of SSRI over placebo, the study was terminated prematurely. Three patients, who became depressed afterwards, were treated in an unblinded fashion with citalopram.

Conclusions: The findings demonstrate clearly that citalopram treatment is highly effective in HCV patients on interferon therapy, when initiated after the onset of clinically relevant depressive symptoms. This suggests that a general SSRI prophylaxis is not necessary in these patients.

Statistics from Altmetric.com

Footnotes

  • Funding: This study was supported in part by Essex Pharma (Munich, Germany), a subsidiary of Schering-Plough (Kenilworth, New Jersey, USA).

  • Ethics approval: Ethics approval was obtained.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Digest
    Robin Spiller Magnus Simren